Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | AKT1 | P31749 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5169982 | 0.95 | CYP2C19 (0.44) | CYP2C19HTTHDAC3HDAC1HDAC2 | |
| Formic Acid SCHEMBL3894178 | 0.84 | ALDH1A1 (0.54) | CYP2C19HTTHDAC3HDAC1HDAC2 | |
| Formic Acid SCHEMBL3897717 | 0.81 | POLB (0.39) | CYP2C19HTTHDAC3HDAC1HDAC2 | |
| SCHEMBL3898644 | 0.78 | HDAC3 (0.36) | HDAC3HDAC1HDAC2HDAC6REN | |
| Formic Acid SCHEMBL3899780 | 0.78 | BACE1 (0.44) | CYP2C19HTTHDAC3HDAC1HDAC2 | |
| Formic Acid SCHEMBL3895024 | 0.78 | ALDH1A1 (0.50) | CYP2C19HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5170508 | 0.77 | ALDH1A1 (0.58) | CYP2C19HTTHDAC3HDAC1HDAC2 | |
| Formic Acid SCHEMBL27679268 | 0.77 | POLB (0.39) | CYP2C19HTTTACR3ALDH1A1AKT1 | |
| Formic Acid SCHEMBL3895033 | 0.77 | PDE2A (0.47) | ALDH1A1KCNH2GAAPDE2A | |
| Hydrochloric Acid SCHEMBL6500497 | 0.75 | DRD2 (0.50) | CYP2C19HTTTACR3ALDH1A1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | CYP2C19 114/4885HTT 564/4885HDAC3 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.